RESUMEN

Immunomodulatory drugs are widely used as drugs for the treatment of inflammatory diseases of microbial etiology in clinical medicine. The authors evaluated the effectiveness of the therapeutic effect of the Cycloferon immunomodulator in the treatment of chronic purulent-inflammatory diseases of the reproductive tract using clinical, microbiological and immunological parameters. It was shown that under the influence of immunomodulatory therapy, the restoration of the qualitative and quantitative composition of the normoflora was observed with the elimination of etiologically significant microorganisms. The immunocorrective effect of therapy on the indices of local immunity was established: the concentration of lactoferrin increased in the cervical secretion, the level of cytokines IL-1ß and γ-IFN normalized, the amount of secretory IgA increased significantly, which contributed to the enhancement of local protective reactions, as well as the clinical efficacy of therapy, which was manifested in the reduction and/or disappearance of pain syndrome and the absence of relapse for 2 or more years. Conducted researches allow us to speak of immunotropic drugs as a promising direction in the treatment of inflammatory processes of the reproductive tract, a significant advantage of which is rational immunomodulation directly in the focus of inflammation, the availability of treatment, the absence of side effects with adequate therapeutic regimens, which makes it relevant to further study this direction of immunocorrection and its implementation into wide clinical practice.

Asunto(s)

Citocinas , Inmunomodulación , Humanos , Inmunidad , Inflamación

RESUMEN

Neuroprotective properties of fullerenols С60(OH)30 and С70(OH)30 have been shown in a Drosophila melanogaster model of Parkinson's Disease (PD). Fullerenols used in this work demonstrated negligible toxicity even at high concentrations as a result of a specifically developed manufacturing process. It has been shown that the drugs promote restoration of dopamine levels, reduce oxidative stress in transgenic flies expressing the human alpha-synuclein gene, prevent death of dopaminergic neurons in the brain and alleviate aggregation of alpha-synuclein. Thus, the anti-aggregation effect of fullerenols, demonstrated for various forms of amyloid proteins, is also observed for alpha-synuclein, resulting in reduction of formation of insoluble aggregates of this protein. Neuroprotective activity was affected by the Drosophila melanogaster genotype and not by the number of carbon atoms in the fullerenol compounds. We concluded that due to their unique properties, fullerenols might be a promising tool for drug development to treat PD.

Asunto(s)

Encéfalo/efectos de los fármacos , Drosophila melanogaster/genética , Fulerenos/farmacología , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Animales , Animales Modificados Genéticamente , Encéfalo/metabolismo , Encéfalo/patología , Modelos Animales de Enfermedad , Dopamina/metabolismo , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/patología , Humanos , Estrés Oxidativo/efectos de los fármacos , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/patología , alfa-Sinucleína/metabolismo

RESUMEN

The study was carried out to investigate possibility of applying biologically active substances - interferon inductors - for increasing effectiveness of prevention and treatment of torpid forms of infectious process, staphylococcus bacteria carrying in particular, considering effectiveness of their effect on biological characteristics of Staphylococcus aureus. The data are obtained concerning character of effect of pharmaceuticals on persistent characteristics of staphylococcus. These results can be applied in selection of new perspective preparations for sanitation of staphylococcus bacteria carrying.